Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:1707-1714

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liggett, S. B.
Right arrow Articles by Dorn, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liggett, S. B.
Right arrow Articles by Dorn, G. W., II
Related Collections
Right arrow Genetically altered mice
Right arrow Myocardial cardiomyopathy disease
Right arrow Receptor pharmacology

(Circulation. 2000;101:1707.)
© 2000 American Heart Association, Inc.


Basic Science Reports

Early and Delayed Consequences of ß2-Adrenergic Receptor Overexpression in Mouse Hearts

Critical Role for Expression Level

Stephen B. Liggett, MD; Nicole M. Tepe, PhD; John N. Lorenz, PhD; Amy M. Canning, BS; Tamara D. Jantz, BS; Sayaka Mitarai, MD; Atsuko Yatani, PhD; Gerald W. Dorn, II, MD

From the Departments of Medicine (S.B.L., A.M.C., T.D.J., G.W.D.) and Pharmacology (S.B.L., N.M.T., J.N.L., S.M., A.Y., G.W.D.), University of Cincinnati Medical Center, Cincinnati, Ohio.

Correspondence to G.W. Dorn II, University of Cincinnati Medical Center, 231 Bethesda Ave, ML 0590, Cincinnati, OH 45267-0590. E-mail dorngw{at}ucmail.uc.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Transgenic cardiac ß2-adrenergic receptor (AR) overexpression has resulted in enhanced signaling and cardiac function in mice, whereas relatively low levels of transgenically expressed G{alpha}s or ß1AR have resulted in phenotypes of ventricular failure. Potential relationships between the levels of ßAR overexpression and biochemical, molecular, and physiological consequences have not been reported.

Methods and Results—We generated transgenic mice expressing ß2AR at 3690, 7120, 9670, and 23 300 fmol/mg in the heart, representing 60, 100, 150, and 350 times background ßAR expression. All lines showed enhanced basal adenylyl cyclase activation but a decrease in forskolin- and NaF-stimulated adenylyl cyclase activities. Mice of the highest-expressing line developed a rapidly progressive fibrotic dilated cardiomyopathy and died of heart failure at 25±1 weeks of age. The 60-fold line exhibited enhanced basal cardiac function without increased mortality when followed for 1 year, whereas 100-fold overexpressors developed a fibrotic cardiomyopathy and heart failure, with death occurring at 41±1 weeks of age. Adenylyl cyclase activation did not correlate with early or delayed decompensation. Propranolol administration reduced baseline +dP/dtmax to nontransgenic levels in all ß2AR transgenics except the 350-fold overexpressors, indicating that spontaneous activation of ß2AR was present at this level of expression.

Conclusions—These data demonstrate that the heart tolerates enhanced contractile function via 60-fold ß2AR overexpression without detriment for a period of >=1 year and that higher levels of expression result in either aggressive or delayed cardiomyopathy. The consequences for enhanced ßAR function in the heart appear to be highly dependent on which signaling elements are increased and to what extent.


Key Words: receptors, adrenergic, beta • cardiomyopathy • heart failure


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Catecholaminergic activation of cardiac ß-adrenergic receptors (ßARs) regulates the acute hemodynamic response to stress or injury by increasing myocardial contractility and heart rate. A deleterious effect of chronic ßAR stimulation is suggested by clinical heart failure studies in which sympathomimetic agents are associated with a poor outcome,1 2 3 by a benefit of ßAR blockade in heart failure,4 5 6 and by reports of catecholamine-induced cardiomyopathies.7 8 9 10 Increasing cardiac adrenergic signaling by overexpressing ßARs or inhibiting the ßAR kinase, however, appears to have therapeutic potential in heart failure, as demonstrated by favorable effects in genetically modified mice. Transgenic overexpression of ß2ARs in mouse cardiomyocytes increased basal and isoproterenol-stimulated adenylyl cyclase activity and enhanced resting cardiac systolic function.11 12 ß2AR overexpression normalized the characteristic resting systolic dysfunction in the G{alpha}q transgenic mouse model of hypertrophy13 but failed to improve a murine genetic dilated cardiomyopathy.14 Interestingly, augmenting ßAR signaling through overexpressing a peptide inhibitor of the ßAR kinase enhanced ßAR-stimulated cardiac function15 and significantly improved function in murine dilated cardiomyopathy14 but not contractile depression in the G{alpha}q hypertrophy model.13 From these results, it appears that at least in mice, chronic enhancement of ßAR signaling can augment contractile function in the normal heart and provide functional benefit. However, the favorable effects reported in ß2AR-overexpressing mice contrast with dilated cardiomyopathy and myocardial fibrosis after overexpression of ß1AR or G{alpha}s, the signaling protein that couples ßAR to adenylyl cyclase.16 17

What is lacking in our understanding of pathological effects of enhanced ßAR signaling is a long-term assessment of signaling, structure, and in vivo function of multiple mouse lines expressing a range of a given signaling protein. To address this, transgenic mice were generated with ß2AR overexpression ranging from 60 to 350 times background. The results reported here confirm a long-term positive inotropic effect of ß2AR overexpression at 60-fold endogenous ßAR levels but also demonstrate that a long-term consequence of ß2AR overexpression at higher levels is progressive myocardial fibrosis, ultimately leading to heart failure.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Transgenic Mice
The wild-type human ß2AR cDNA was ligated into the Sal-1 site (exon 3) of the full-length 5.5-kb {alpha}-myosin heavy chain promoter essentially as previously described.12 The linearized constructs were injected into male pronuclei of fertilized FVB/N mouse oocytes and implanted into pseudopregnant female oviducts. Thirteen founders were identified by genomic Southern analysis.

Analysis of Cardiac Function
In vivo ventricular function was measured with invasive and noninvasive techniques essentially as previously described12 18 19 in lightly anesthetized (ketamine/thiobutabarbital), spontaneously breathing, closed-chest mice. Noninvasive cardiac function was assessed by 2D guided M-mode echocardiography of tribromoethanol-anesthetized mice. In some cases, studies were performed before and after intraperitoneal administration of 100 ng/g isoproterenol.

Assessment of Cardiac Hypertrophy
Hypertrophy was assessed gravimetrically by an analytical balance and by RNA dot-blot Northern analysis of hypertrophy-associated genes as previously described.18 19

ßAR Signaling Studies
Radioligand binding with 125I-cyanopindolol to ventricular membranes was performed as previously described.12 13 For adenylyl cyclase activities, ventricular membranes ({approx}10 µg) were coincubated with (mmol/L) phosphoenolpyruvate 2.8, GTP 0.06, ATP 0.12, cAMP 0.1, and ascorbic acid 0.1; and 4 U/mL myokinase, 10 U/mL pyruvate kinase, and 3x106 dpm [{alpha}-32P]ATP for 10 minutes at 37°C with various concentrations of isoproterenol, 10 mmol/L NaF, or 100 µmol/L forskolin. Reactions were stopped by dilution with 1.0 mL of a 4°C solution containing excess ATP and cAMP and 25 000 dpm/mL [3H]cAMP (used for column recovery). [32P]cAMP was separated by chromatography over alumina columns. GRK2 and Gi{alpha}2/3 were measured in whole-heart homogenates by immunoblotting using standard techniques and antibodies from Santa Cruz Biotechnology as we have previously described in detail.20 21

Measurement of Calcium Currents
Whole-cell patch clamp studies were performed on ventricular cardiomyocytes as described previously.22 23 In the studies of basic Ca2+ channel kinetics, cells were dialyzed with 5 mmol/L EGTA. For isoproterenol experiments, EGTA was replaced with 10 mmol/L BAPTA to prevent Ca2+-dependent inactivation.24

Statistical Analysis
Unless stated otherwise, data are presented as mean±SEM. Transgenic mice from a single line and nontransgenic littermates were compared by 2-tailed Student’s t test. Multiple comparisons between different lines or at different ages within 1 line were performed with 1-way ANOVA followed by a Bonferroni procedure. In vivo dose-response data were analyzed by a mixed-factor ANOVA, with repeated measures on the second factor. A value of P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
To better understand the effects of cardiac ß2AR overexpression, we created a series of ß2AR-overexpressing mouse lines in the FVB/N background with a range in transgene copy number. Of 13 founder mice, 1 failed to breed; 3 failed to transmit the transgene to progeny, suggesting that they were chimeric; independent lines were established for 5 founders; 4 other founders died before breeding; and 1 established line was lost before the present studies. The 4 founders that died had massive cardiac enlargement with dilated atria (Figure 1Down), pulmonary congestion, and pleural effusions.



View larger version (55K):
[in this window]
[in a new window]
 
Figure 1. Cardiac phenotype of ß2AR-overexpressing mice. A, A 25-week-old ß2-60 mouse has normal size heart and no gross or microscopic abnormalities. B, A 25-week-old ß2-350 mouse exhibits 4-chamber enlargement with severe left ventricular dilatation and atrial mural thrombi. Histological examination of this heart revealed severe fibrotic replacement of left ventricular myocardium (see Figure 4AUp). C, One of 4 ß2AR-overexpressing founder mice that died of heart failure. Left atrium (LA) is massively enlarged with extensive laminar thrombus. Left ventricle (LV) is enlarged and hypertrophied. RV indicates right ventricle.

Pharmacological Properties
The 4 successfully propagated {alpha}-myosin heavy chain ({alpha}MHC)–ß2AR transgenic lines exhibited a range of ß2AR expression (125I-cyanopindolol binding; Table 1Down) {approx}60-, 100-, 150-, and 350-fold greater than nontransgenic and were so designated (ß2-60, etc). Results from adenylyl cyclase studies are shown in Figure 2Down and Table 1Down. When normalized to NaF stimulation (Figure 2BDown), basal activities were increased {approx}3-fold in the 2 lowest-expressing lines and {approx}2-fold in the 2 higher-expressing lines. The extent of maximal isoproterenol stimulation was also increased with each line compared with nontransgenic. However, the maximal increase was not commensurate with the increase in basal, so the fold stimulation over basal was in fact decreased. Absolute levels of activity (pmol · min-1 · mg-1) are shown in Figure 2ADown and Table 1Down. As can be seen, only the ß2-60 line had higher basal activities when the data are expressed in this way. Both NaF- and forskolin-stimulated adenylyl cyclase activities were depressed to similar extents in all transgenic lines (Figure 2Down, C and D), suggesting that a compensatory event distal to the receptor occurs with chronic overexpression of ß2AR at these levels. We therefore assessed by immunoblotting possible changes in expression of ßAR kinase (GRK2) or Gi{alpha}, both of which are known to alter ßAR signaling when increased in the heart. Neither ßAR kinase nor Gi{alpha}2/3 levels were increased in any of the ß2AR overexpressors (data not shown). Immunoreactivity of adenylyl cyclase type V/VI was not sufficient for accurate determination, so it is not possible to exclude a change in adenylyl cyclase expression with ß2AR overexpression.


View this table:
[in this window]
[in a new window]
 
Table 1. Characteristics of ß2AR-Overexpressing Mouse Lines



View larger version (30K):
[in this window]
[in a new window]
 
Figure 2. Agonist stimulation of cardiac adenylyl cyclase activity in ß2AR-overexpressing mice. A, Agonist-stimulated adenylyl cyclase activity of transgenic and nontransgenic animals. B, Isoproterenol-stimulated adenylyl cyclase activity in cardiac membranes of nontransgenic and ß2AR overexpressing mice normalized to NaF activation. Shown are means of 4 to 7 experiments per line. Error bars are omitted for clarity (see Table 1Up). C and D, NaF- and forskolin-stimulated activities.

Early Effects
Initial phenotypic characterizations and interline comparisons of mice 10 to 15 weeks old demonstrated pathology in ß2-350 mice. Gross morphological analysis revealed a 25% increase in heart weight of the ß2-350 line compared with the other ß2AR lines or with nontransgenic littermates (Table 1Up). Whereas echocardiographic left ventricular fractional shortening was enhanced in the 3 lower-expressing ß2AR lines (Table 1Up), ß2-350 exhibited impaired left ventricular function with ventricular enlargement (Table 1Up). Increased cardiac ßMHC and atrial natriuretic factor gene expression, characteristic features of cardiac hypertrophy, were also detected only in ß2-350 mice (see Table 1Up and below). Furthermore, whereas the 3 lower-expressing ß2AR lines showed no histological evidence of fibrosis or cardiomyocyte hypertrophy (not shown), ß2-350 hearts showed replacement fibrosis (see below). Thus, young adult mice expressing ß2AR at 350 times normal levels developed cardiomegaly, increased expression of hypertrophy-associated genes, and depressed systolic function, whereas multiple transgenic lines with lower ß2AR expression levels had normal cardiac size and gene expression with enhanced systolic function.

Late Effects
Because cardiomegaly, fetal gene expression, and fibrosis in young adult mice were observed only in the highest-expressing ß2AR transgenic line, we considered that a longitudinal analysis of ß2AR overexpressors might detect additional phenotypic features related to duration of transgene expression. Cohorts of 20 to 30 mice from each of 3 lines (ß2-60, -100, and -350) were therefore prospectively followed for 1 year. No increase in all-cause mortality was found in ß2-60 mice compared with nontransgenic littermates during this period (Figure 3Down). Early mortality was, however, observed in ß2-350 mice, which died at 25±1 weeks (Figure 3Down), suggesting an association between high levels of ß2AR expression and early death. The cause of death appeared to be left heart failure, as shown by pulmonary congestion (increased lung weights) and massive cardiac enlargement (Table 2Down). ß2-100 mice also developed cardiac enlargement, heart failure, and premature death, but death occurred at 41±1 weeks (Figure 3Down, Table 2Down). Thus, these longitudinal mortality data demonstrate delayed deleterious effects of ß2AR overexpression that are proportional in severity and rapidity of progression to the level of cardiac ß2AR.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 3. Impaired survival of high-level ß2AR overexpressors. Kaplan-Meier survival curve of ß2AR-overexpressing mouse lines followed for 50 weeks.


View this table:
[in this window]
[in a new window]
 
Table 2. Characteristics of ß2AR-Overexpressing Mice That Develop Heart Failure

Because these studies indicated that mortality in ß2-350 mice was a function of the age of the animal, histological, morphometric, and molecular analyses were performed at 7, 11, and 17 weeks of age. These studies showed that the decline in left ventricular function was associated with cardiomyocyte dropout and fibrotic replacement. Fibrosis was not evident at 7 weeks, was apparent at 11 weeks, and was marked by 17 weeks of age (Figure 4ADown). The pattern of fetal cardiac gene expression remained constant over time (Figure 4BDown).



View larger version (110K):
[in this window]
[in a new window]
 
Figure 4. Cardiac deterioration with high levels of ß2AR. A, Representative Masson’s trichrome stains (magnification x100) of full-thickness apical left ventricular free wall from 7-, 11-, 17-, and 25-week-old ß2-350 overexpressors showing progressive cardiomyocyte loss and fibrotic replacement with increasing age. The 25-week heart depicted is same as that shown in Figure 1BUp. B, RNA dot-blot analysis of cardiac gene expression shows a pattern of increased fetal gene expression in 7-, 11-, and 17-week-old ß2-350 mice. SERCA indicates sarcoplasmic reticulum calcium ATPase; ANF, atrial natriuretic factor; sk, skeletal; card, cardiac; and PLB, phospholamban.

In Vivo Hemodynamics
To more rigorously assess the effects of ß2AR density and duration of expression on cardiac functional status, we performed in vivo hemodynamic studies on 12- and 20- to 24-week ß2-350 mice compared with 12-week ß2-60 mice. Whereas baseline heart rates were significantly increased in ß2-60, heart rates were not increased in either 12- or 20-week-old ß2-350 mice (Table 3Down). Basal +dP/dt was doubled in ß2-60 mice and increased in 12-week-old but not {approx}20-week-old ß2-350 mice (Table 3Down). Thus, enhanced basal cardiac systolic function was observed in mice expressing lower levels of ß2AR and in younger mice expressing high levels of ß2AR. With development of cardiomegaly in the latter mice, resting systolic function decreased.


View this table:
[in this window]
[in a new window]
 
Table 3. Invasive Hemodynamic Studies of ß2AR Overexpressors

Because cardiac phenotypes resulting from ß2AR overexpression may be a consequence of either enhanced agonist-stimulated ßAR function or an increase in spontaneous receptor activation,11 we assessed hemodynamic responsiveness to isoproterenol. As shown in Table 3Up and Figure 5ADown, inotropic and chronotropic responses to isoproterenol were generally blunted in the ß2AR-overexpressing mice. In ß2-60 mice, this was because basal heart rate and +dP/dt were already near maximal. Likewise, echocardiographic left ventricular fractional shortening was increased by isoproterenol in nontransgenic mice (44±3% basal, 61±3% isoproterenol, P<0.001) but not in ß2-60 mice (54±3% basal, 56±4% isoproterenol, P=NS). However, in ß2-350 mice, there was no dP/dt response to isoproterenol, whether basal values were increased (12 week) or normal (20 week) (Table 3Up, Figure 5ADown). The response to nonselective ßAR blockade with intravenous propranolol was used to distinguish between agonist-dependent and -independent effects of overexpressed ß2AR (Figure 5BDown). Propranolol prevented isoproterenol-mediated increases in +dP/dt in nontransgenic mice, demonstrating the adequacy of the dose used. Basal +dP/dt, which was elevated in the ß2-60 mice, was normalized by propranolol. At 12 weeks of age, when ß2-350 mice had significantly elevated basal dP/dt, propranolol failed to normalize contractility. Thus, a critical difference between the ß2AR overexpressors may be endogenous agonist participation in enhanced cardiac function at lower levels of ß2AR but predominantly agonist-independent ß2AR effects at higher levels of receptor expression.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 5. Hemodynamic consequences of high- and low-level ß2AR overexpression. A, Left ventricular dP/dtmax for ß2-60 and ß2-350 mice (12 and 20 weeks) as a function of intravenous isoproterenol dose. Each point represents mean of results from 4 animals per group. B, ßAR blockade with intravenous propranolol reverses basal enhancement of dP/dt in 12-week-old ß2-60 mice but not 12-week-old ß2-350 mice.

Ca2+ Channel Activity
To confirm that the observed perturbations in cardiac function, myocyte signaling, and adenylyl cyclase activity did not simply reflect increased fibrotic content of ß2-350 hearts, patch-clamp studies of inward calcium currents (ICa) were performed on ventricular cardiomyocytes from {approx}12- and {approx}24-week-old ß2-350 mice. Cardiomyocyte capacitance, a measure of cell size, was significantly increased compared with nontransgenic siblings at 12 weeks (159.1±4.2 pF, n=129 versus 143.7±4.8 pF, n=67) and 24 weeks (274.7±14 pF, n=41 versus 145.4±5.8 pF, n=59; P<0.05), consistent with the molecular and morphometric indices of cardiac hypertrophy noted above. Whereas the voltage dependence of ICa in ß2-350 cells was not altered, ICa density (shown in Figure 6ADown) was significantly reduced compared with that in nontransgenic cells (5.0±0.3 pA/pF, n=24 versus 8.9±0.4 pA/pF, n=38 at 12 weeks; 5.2±0.5 pA/pF, n=12 versus 10.3±0.6 pA/pF, n=26 at 24 weeks, P<0.05). Myocytes from {approx}24-week ß2-350 mice showed significantly reduced isoproterenol responsiveness ({approx}50% of control) without any change in EC50 (Figure 6BDown). These results demonstrate progressive cardiomyocyte ßAR-Ca2+ dysfunction in aging ß2-350 mice.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 6. ß2-350 cardiomyocyte electrophysiological properties. A, Representative whole-cell ICa recorded in nontransgenic (NTG) and ß2-350–overexpressing myocytes at 24 weeks of age. B, Concentration-dependent effects of isoproterenol (Iso) on ICa for NTG and ß2AR-overexpressing myocytes. EC50s were 26.5±6.9, 8.2±4.7, and 43.0±30 nmol/L for NTG, ß2-350–overexpressing mice at 12 weeks, and the same at 24 weeks, respectively. Data are mean±SEM from 6 to 40 cells.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The objective of these studies was to establish a "transgene dose-response" for ß2AR expression in the heart. In pursuit of this objective, we created a series of cardiac-specific ß2AR transgenic mice and found that the range of ß2AR expression was associated with a spectrum of phenotypes: (1) enhanced contractile function in young mice with ß2AR levels 60 times normal; (2) rapidly progressive fibrosis, cardiac hypertrophy, and heart failure with ß2AR levels 350 times normal; and (3) early enhanced function with delayed development of fibrotic cardiomyopathy at intermediate expression levels. Enhanced baseline function accruing from ß2AR overexpression at levels 60 times normal occurred in the absence of any detectable pathological consequences over a 1-year period. Although the ß2-60 overexpressing mice are similar to ß2AR transgenic mice initially reported by Lefkowitz and coworkers11 and by us,12 it is of course not possible to exclude the possibility that pathological characteristics may eventually develop in ß2-60 mice as they continue to age. The particularly important findings of the present studies, however, pertain to the ß2-100 and -350 lines, which exhibited progressive ventricular dysfunction, directly related in severity and rapidity of progression to the level of ß2AR expression. With all lines, we observed a decrease in NaF- and forskolin-stimulated activities, but the ßAR signaling appears to be even further dampened in the higher-expressing lines. Physiologically, this is manifested as lower systolic function with a lack of responsiveness to agonist, which is common in both. This further loss of ventricular function may be due to a decrease in L-type Ca2+ channel density, as observed in the ß2-350 mice, or some other post–receptor-effector derangement.

Another important distinction between the rapidly progressive ß2-350 and ß2-60 lines is the evidence for intrinsic receptor signaling activity. Catheterization-based hemodynamic studies in ß2-350 mice showed no effect of ß2AR blockade with propranolol, whereas in ß2-60 mice, propranolol normalized the basal enhanced contractile function. As a neutral antagonist, propranolol would be expected to block endogenous catecholamine activation of the receptor but not the spontaneous transition of a proportion of ß2AR to the active (R*) conformation. It is interesting to speculate that the unrestricted signaling activity of R* in the ß2-350 line contributes to its aggressive cardiomyopathy. Thus, expression of ß2AR at a level that enhances the in vivo response to agonists but does not cause in vivo ligand-independent signaling may improve cardiac function without deleterious effects. However, exceeding the putative threshold for ligand-independent ß2AR receptor signaling may cause rapid development of the cardiomyopathic syndrome reported here, as well as additional counterregulatory effects not observed with the other lines.

The pathological and physiological characteristics exhibited by the older ß2-350 and ß2-100 mice reproduce some features of catecholamine cardiomyopathy as described in human subjects with pheochromocytomas.7 8 9 10 The pathophysiology of catecholamine-mediated cardiomyopathy has been postulated to result from ischemic necrosis secondary to intense vasospasm or from direct toxic effects of oxidized catecholamines. Our studies demonstrate that none of these putative mechanisms are necessary for development of cardiomyopathy, because ß2ARs were selectively overexpressed in cardiac myocytes, and there is no reason to believe that circulating or local catecholamine levels are increased in these mice. Rather, these studies and those with the previously reported ß1AR- and G{alpha}s-overexpressing models16 17 support a direct effect of chronic unrestricted ßAR signaling on cardiomyocytes, a notion consistent with catecholamine cardiomyocyte toxicity demonstrated in some tissue culture studies.25

The variability in adenylyl cyclase responsiveness in the various ß2AR overexpressors suggests that regulatory mechanisms may be evoked by certain levels of long-term overexpression that seem to partially desensitize receptor signaling. Changes in the expression of ßAR kinase,26 G{alpha}i, and adenylyl cyclase27 in the heart have been reported to be associated with decreased ßAR signaling. An increase in ßAR kinase would be expected to exclusively alter receptor-mediated stimulation, which is not the case in these ß2AR overexpressors, in which we find forskolin- and NaF-stimulated activities also depressed, and ßAR kinase protein expression was not altered in any of the ß2AR lines. An increase in G{alpha}i could theoretically alter basal, ßAR-mediated, and NaF-mediated signaling; however, we found no evidence of such an increase. Finally, we also considered that a decrease in adenylyl cyclase expression could serve to decrease signaling at baseline and in response to agonist, forskolin, and NaF. Indeed, given the above, a decrease in adenylyl cyclase expression seems to be quite a reasonable candidate. However, we are unable to quantitatively assess type V/VI adenylyl cyclase expression in the mouse heart, so we cannot reach a conclusion in this regard.

We have shown that cardiac ß2AR overexpression 60 times background results in enhanced in vitro and in vivo signaling without apparent pathological consequences in mice up to 1 year old. Higher levels of expression result in delayed (ß2-100) or rapidly progressive (ß2-350) cardiomyopathies. That deleterious effects can occur at some level of ß2AR expression is not altogether surprising. The obverse finding, that moderate levels of overexpression are apparently not detrimental, is contrary to the notion heralded by some that enhanced ßAR-Gs–adenylyl cyclase signaling by any means is universally deleterious. Indeed, it is notable that cardiomyopathy caused by ß1AR overexpression is observed at 5 to 15 times endogenous ßAR levels,17 whereas a 60-fold increase in ß2AR appears to be well tolerated. Thus, overly broad generalizations regarding potential deleterious effects of ßAR signaling via increased ß1AR, ß2AR, or G{alpha}s or via inhibition of ßARK may be overly simplistic, because there appear to be fundamental differences in signaling evoked by these mechanisms.


*    Acknowledgments
 
This study was supported by grants GM-54169, HL-58010, HL 22619, and P50-HL-52318 from the National Institutes of Health.

Received August 13, 1999; revision received October 18, 1999; accepted November 5, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Krell JJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986;112:787–791.[Medline] [Order article via Infotrieve]
  2. Lambertz H, Meyer J, Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation. 1984;69:298–305.[Abstract/Free Full Text]
  3. Xamoterol in Severe Heart Failure study group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6.[Medline] [Order article via Infotrieve]
  4. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, Metoprolol in Dilated Cardiomyopathy (MDC) trial study group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441–1446.[Medline] [Order article via Infotrieve]
  5. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678–1687.
  6. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–1231.
  7. Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med. 1966;274:1102–1108.
  8. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med. 1987;316:793–797.[Medline] [Order article via Infotrieve]
  9. Behrana AJ, Hasleton P, Leen CLS, Ashleigh RS, Gholkar A. Multiple extra-adrenal paragangliomas associated with catecholamine cardiomyopathy. Eur Heart J. 1989;10:182–185.[Abstract/Free Full Text]
  10. Sardesai SH, Mourant AJ, Sivathandon Y, Farrow R, Gibbons DO. Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J. 1990;63:234–237.[Abstract/Free Full Text]
  11. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the ß2-adrenergic receptor. Science. 1994;264:582–586.[Abstract/Free Full Text]
  12. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signalling defects and impaired cardiac function of a human ß2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:10483–10488.[Abstract/Free Full Text]
  13. Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low-and high-level transgenic expression of ß2-adrenergic receptors differentially affects cardiac hypertrophy and function in G{alpha}q overexpressing mice. Proc Natl Acad Sci U S A. 1999;96:6400–6405.[Abstract/Free Full Text]
  14. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000–7005.[Abstract/Free Full Text]
  15. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the ß-adrenergic receptor kinase or a ßARK inhibitor. Science. 1995;268:1350–1353.[Abstract/Free Full Text]
  16. Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej RK, Wagner TE, Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, Vatner SF. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol. 1997;272:H585–H589.[Abstract/Free Full Text]
  17. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059–7064.[Abstract/Free Full Text]
  18. D’Angelo DD, Sakata Y, Lorenz JN, Boivin JN, Walsh RA, Liggett SB, Dorn GW II. Transgenic G{alpha}q overexpression induces cardiac contractile function in mice. Proc Natl Acad Sci U S A. 1997;94:8121–8126.[Abstract/Free Full Text]
  19. Sakata Y, Lorenz JN, Hoit BD, Liggett SB, Walsh RA, Dorn GW II. Decompensation of pressure-overload hypertrophy in G{alpha}q-overexpressing mice. Circulation. 1998;97:1488–1495.[Abstract/Free Full Text]
  20. McGraw DW, Forbes SL, Witte DP, Fortner CN, Paul RJ, Liggett SB. Transgenic overexpression of ß2 -adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity. J Biol Chem. 1999;32241–32247.
  21. Jewell-Motz EA, Donnelly ET, Eason MG, Liggett SB. Agonist-mediated downregulation of G{alpha}i via the {alpha}2-adrenergic receptor is targeted by receptor-Gi interaction and is independent of receptor signaling and regulation. Biochemistry. 1998;37:15720–15725.[Medline] [Order article via Infotrieve]
  22. Masaki H, Sato Y, Luo W, Kranias EG, Yatani A. Phospholamban deficiency alters inactivation kinetics of L-type Ca2+ channels in mouse ventricular myocytes. Am J Physiol. 1997;272:H606–H612.[Abstract/Free Full Text]
  23. Sato Y, Ferguson DG, Sako H, Dorn GW II, Kadambi VJ, Yatani A, Hoit BD, Walsh RA, Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem. 1998;273:28470–28477.[Abstract/Free Full Text]
  24. Sako H, Sperelakis N, Yatani A. Ca2+ entry through cardiac L-type Ca2+ channels modulate ß-adrenergic stimulation in mouse ventricular myocytes. Pflugers Arch. 1998;435:749–752.[Medline] [Order article via Infotrieve]
  25. Padua RR, Kardami E. Increased basic fibroblast growth factor (bFGF) accumulation and distinct patterns of localization in isoproterenol-induced cardiomyocyte injury. Growth Factors. 1993;8:291–306.[Medline] [Order article via Infotrieve]
  26. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of ß-adrenergic receptor desensitization in cardiac hypertrophy is increased ß-adrenergic receptor kinase. J Biol Chem. 1997;272:17223–17229.[Abstract/Free Full Text]
  27. Böhm M, Gierschik P, Knorr A, Larisch K, Weismann K, Erdmann E. Desensitization of adenylate cyclase and increase of Gi{alpha} in cardiac hypertrophy due to acquired hypertension. Hypertension. 1992;20:103–112.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Circ. Res.Home page
L. E. Vinge, P. W. Raake, and W. J. Koch
Gene Therapy in Heart Failure
Circ. Res., June 20, 2008; 102(12): 1458 - 1470.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. M. Witteles and M. B. Fowler
Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Srivastava, B. Chandrasekar, Y. Gu, J. Luo, T. Hamid, B. G. Hill, and S. D. Prabhu
Downregulation of CuZn-superoxide dismutase contributes to {beta}-adrenergic receptor-mediated oxidative stress in the heart
Cardiovasc Res, June 1, 2007; 74(3): 445 - 455.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. L. Reudelhuber, K. E. Bernstein, and P. Delafontaine
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
Hypertension, June 1, 2007; 49(6): 1196 - 1201.
[Full Text] [PDF]


Home page
CirculationHome page
K. E. Yutzey and J. Robbins
Principles of Genetic Murine Models for Cardiac Disease
Circulation, February 13, 2007; 115(6): 792 - 799.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
J. G. Burniston, L.-B. Tan, and D. F. Goldspink
Relative myotoxic and haemodynamic effects of the {beta}-agonists fenoterol and clenbuterol measured in conscious unrestrained rats
Exp Physiol, November 1, 2006; 91(6): 1041 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. J. Matkovich, A. Diwan, J. L. Klanke, D. J. Hammer, Y. Marreez, A. M. Odley, E. W. Brunskill, W. J. Koch, R. J. Schwartz, and G. W. Dorn II
Cardiac-Specific Ablation of G-Protein Receptor Kinase 2 Redefines Its Roles in Heart Development and {beta}-Adrenergic Signaling
Circ. Res., October 27, 2006; 99(9): 996 - 1003.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and G. J. Gross
Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1746 - H1753.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
X.-J. Du, X.-M. Gao, H. Kiriazis, X.-L. Moore, Z. Ming, Y. Su, A. M. Finch, R. A. Hannan, A. M. Dart, and R. M. Graham
Transgenic {alpha}1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival
Cardiovasc Res, September 1, 2006; 71(4): 735 - 743.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Kiriazis, X.-J. Du, X. Feng, E. Hotchkin, T. Marshall, S. Finch, X.-M. Gao, G. Lambert, J. K. Choate, and D. M. Kaye
Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1359 - H1365.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. B. Liggett
Lymphocyte GRK levels as biomarkers in heart failure
Eur. Heart J., September 1, 2005; 26(17): 1695 - 1696.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Ait-Mamar, M. Cailleret, C. Rucker-Martin, A. Bouabdallah, G. Candiani, C. Adamy, P. Duvaldestin, F. Pecker, N. Defer, and C. Pavoine
The Cytosolic Phospholipase A2 Pathway, a Safeguard of {beta}2-Adrenergic Cardiac Effects in Rat
J. Biol. Chem., May 13, 2005; 280(19): 18881 - 18890.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J. G. Burniston, L.-B. Tan, and D. F. Goldspink
{beta}2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle
J Appl Physiol, April 1, 2005; 98(4): 1379 - 1386.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. Syed, A. Odley, H. S. Hahn, E. W. Brunskill, R. A. Lynch, Y. Marreez, A. Sanbe, J. Robbins, and G. W. Dorn II
Physiological Growth Synergizes With Pathological Genes in Experimental Cardiomyopathy
Circ. Res., December 10, 2004; 95(12): 1200 - 1206.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. Hamada, M. Suzuki, S. Yuasa, N. Mimura, N. Shinozuka, Y. Takada, M. Suzuki, T. Nishino, H. Nakaya, H. Koseki, et al.
Dilated Cardiomyopathy Caused by Aberrant Endoplasmic Reticulum Quality Control in Mutant KDEL Receptor Transgenic Mice
Mol. Cell. Biol., September 15, 2004; 24(18): 8007 - 8017.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. Covolo, U. Gelatti, M. Metra, S. Nodari, A. Piccichè, N. Pezzali, C. Zani, A. Alberti, F. Donato, G. Nardi, et al.
Role of {beta}1- and {beta}2-adrenoceptor polymorphisms in heart failure: a case-control study
Eur. Heart J., September 1, 2004; 25(17): 1534 - 1541.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Grandy, E. M. Denovan-Wright, G. R. Ferrier, and S. E. Howlett
Overexpression of human {beta}2-adrenergic receptors increases gain of excitation-contraction coupling in mouse ventricular myocytes
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1029 - H1038.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Ahmet, M. Krawczyk, P. Heller, C. Moon, E. G. Lakatta, and M. I. Talan
Beneficial Effects of Chronic Pharmacological Manipulation of {beta}-Adrenoreceptor Subtype Signaling in Rodent Dilated Ischemic Cardiomyopathy
Circulation, August 31, 2004; 110(9): 1083 - 1090.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Barki-Harrington, C. Perrino, and H. A Rockman
Network integration of the adrenergic system in cardiac hypertrophy
Cardiovasc Res, August 15, 2004; 63(3): 391 - 402.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Rosenkranz
TGF-{beta}1 and angiotensin networking in cardiac remodeling
Cardiovasc Res, August 15, 2004; 63(3): 423 - 432.
[Abstract] [Full Text] [PDF]